Literature DB >> 2156885

Effect of leuprolide and dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism.

R S Rittmaster1, D L Thompson.   

Abstract

Ten hirsute women with polycystic ovarian syndrome (PCO) and nine with idiopathic hirsutism (IH) underwent selective ovarian suppression with leuprolide for 5-6 months and then were randomized to receive, in addition, dexamethasone or placebo for 4 more months. Serum hormone levels and hair growth rates were determined before and after each treatment period. During the initial treatment period with leuprolide alone, testosterone decreased by 54 +/- 6% (mean +/- SEM) in PCO and by 36 +/- 3% in IH (P = 0.02). Androstenedione decreased by 53 +/- 6% in PCO and by 31 +/- 7% in IH (P = 0.02). Androstanediol glucuronide (Adiol-G) decreased by 14 +/- 6% in PCO and by 7 +/- 3% in IH. There was no change in dehydroepiandrosterone sulfate (DHEAS). While initial serum androgen levels were higher in PCO than in IH, they were similar after ovarian suppression in the two groups. After ovarian suppression, Adiol-G was more consistently correlated with testosterone and androstenedione than was DHEAS, suggesting that Adiol-G may be a better marker than DHEAS of adrenal androgen secretion. Hair growth rates decreased by 37 +/- 6% in PCO and by 14 +/- 10% in IH (P = 0.07). The change in hair growth correlated with the change in androstenedione (r = 0.66; P = 0.002), but not significantly with the change in testosterone (r = 0.29; P = 0.2). After the addition of dexamethasone therapy (0.5 mg daily), testosterone, androstenedione, and DHEAS levels fell to near or below assay detection limits, while Adiol-G decreased by 80 +/- 3%. Hair growth rates decreased slightly more in women during dexamethasone (46 +/- 6%) than during placebo (26 +/- 9%; P = 0.18). In summary, the ovary was the major source of circulating testosterone and androstenedione in PCO. The adrenal contributed a substantial minority of these hormones in PCO and was the major source of androgen secretion in IH. Adrenal hyperandrogenism was common in both IH and PCO. Hair growth rates correlated best with changes in serum androstenedione levels. Adiol-G, which was derived primarily from adrenal precursors, was a better marker of adrenal androgen secretion than was DHEAS in these subjects.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156885     DOI: 10.1210/jcem-70-4-1096

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Hirsutism: pilosebaceous unit dysregulation. Role of peripheral and glandular factors.

Authors:  V Toscano
Journal:  J Endocrinol Invest       Date:  1991-02       Impact factor: 4.256

2.  Management of hirsutism.

Authors:  L M Kettel
Journal:  West J Med       Date:  1992-06

Review 3.  Polycystic ovary syndrome in adolescence.

Authors:  Colleen Buggs; Robert L Rosenfield
Journal:  Endocrinol Metab Clin North Am       Date:  2005-09       Impact factor: 4.741

4.  Long-term effects on bone mineral density and bone metabolism of 6 months' treatment with gonadotropin-releasing hormone analogues in Japanese women: comparison of buserelin acetate with leuprolide acetate.

Authors:  Kazuya Makita; Ken Ishitani; Hiroaki Ohta; Fumi Horiguchi; Shiro Nozawa
Journal:  J Bone Miner Metab       Date:  2005       Impact factor: 2.626

5.  Functional hyperandrogenism detected by corticotropin and GnRH-analogue stimulation tests in women affected by apparently idiopathic hirsutism.

Authors:  R Rossi; L Tauchmanovà; A Luciano; R Valentino; S Savastano; C Battista; M Di Martino; G Lombardi
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

Review 6.  Polycystic ovary syndrome in the pediatric population.

Authors:  Andrew A Bremer
Journal:  Metab Syndr Relat Disord       Date:  2010-10       Impact factor: 1.894

7.  Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; P Morosini; R De Pirro
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

8.  Pathways leading to phosphorylation of p450c17 and to the posttranslational regulation of androgen biosynthesis.

Authors:  Meng Kian Tee; Qing Dong; Walter L Miller
Journal:  Endocrinology       Date:  2008-01-10       Impact factor: 4.736

Review 9.  The adrenal and polycystic ovary syndrome.

Authors:  Bulent O Yildiz; Ricardo Azziz
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

Review 10.  Gonadotrophin-releasing hormone agonists. A guide to use and selection.

Authors:  M Filicori
Journal:  Drugs       Date:  1994-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.